Name: Latest research reports of Gland Pharma Ltd. authored by Axis Direct and published by - Trendlyne research reports.
Item: Gland Pharma Ltd.
Rating: 3
Author: Axis Direct

Gland Pharma Ltd.

NSE: GLAND | BSE: 543245 | ISIN: INE068V01023 | Industry: Pharmaceuticals
| Mid-range Performer

1592.4000 -12.45 (-0.78%)

NSE Mar 28, 2025 15:59 PM

28.30% Fall from 52W High

Volume: 60,089

High vol. this week

Gland Pharma Ltd.

19 May 2023

1592.40

-0.78%

Result Update:Gland Pharma

Hold: Gland Pharma Ltd.

Target

Axis Direct

Company Outlook & Guidance: Injectable companies (HIKMA, HOSIPORA, and Aurobindo) in the US market sales grew by ~4% YoY. We expect similar growth for GLAND in the core markets over a longer period and high single-digit growth in India and RoW over a long-term outlook.

Gland Pharma Ltd. average weekly volume is high.